We caught up with Jose Gonzalez-Juanatey to discuss his highlights from this year’s meeting.
Speaker disclosures: Jose Gonzalez-Juanatey has received research grants from: Boehringer-Ingelheim, Novartis, Bayer, AstraZeneca, and been a speaker or consultant to: Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daichii-Sankyo, Ferrer International, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier.
Support: Interview and filming supported by Touch Medical Media and conducted by Nicola Cartridge.
Filmed during a remote video call with Jose Gonzalez-Juanatey as a highlight of ACC 2021, May 2021.
Share this Video
Related Videos In Myocardial Infarction
Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study
Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]
Marc A Pfeffer, ACC 2021 – Meeting highlights
Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) kindly shared his highlights from Virtual ACC 2021. Speaker disclosures: Marc A Pfeffer has received consulting fees/honorarium from: Novo Nordisk, AstraZeneca Pharmaceuticals, DalCor, GlaxoSmithKline, Sanofi-Aventis, Boehringer Ingelheim-Lilly, Corvidia, Peerbridge, Novartis; Research/research grants from: Novartis; Other financial benefit: Novartis, DalCor Support: Interview […]
Marc A Pfeffer, ACC 2021 – Findings from PARADISE-MI
We were delighted to have the opportunity to speak with Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) to discuss the PARADISE-MI trial investigating sacubitril/valsartan vs. ramipril in a contemporary enriched AMI population, presented at ACC 2021. Abstract Title: Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!